Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Net Income (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Net Income for 9 consecutive years, with -$8000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Net Income rose 27.27% year-over-year to -$8000.0, compared with a TTM value of -$24000.0 through Dec 2025, up 11.11%, and an annual FY2025 reading of $253000.0, up 1037.04% over the prior year.
  • Net Income was -$8000.0 for Q2 2025 at VYNE Therapeutics, roughly flat from -$8000.0 in the prior quarter.
  • Across five years, Net Income topped out at $13.4 million in Q1 2022 and bottomed at -$9.7 million in Q1 2021.
  • Average Net Income over 5 years is -$1.1 million, with a median of -$37000.0 recorded in 2023.
  • The sharpest move saw Net Income soared 238.14% in 2022, then crashed 151.47% in 2023.
  • Year by year, Net Income stood at -$3.2 million in 2021, then skyrocketed by 32.3% to -$2.2 million in 2022, then skyrocketed by 98.29% to -$37000.0 in 2023, then skyrocketed by 78.38% to -$8000.0 in 2024, then changed by 0.0% to -$8000.0 in 2025.
  • Business Quant data shows Net Income for VYNE at -$8000.0 in Q2 2025, -$8000.0 in Q1 2025, and -$8000.0 in Q4 2024.